Additionally, patients with MDS-IB2 could be classified as having MDS with EB (n = 19, peripheral blast 5–9%), MDS with mutated TP53 (n = 1, single TP53 mutation with VAF 41.2% and complex karyotype), MDS/AML with mutated TP53 (n = 8), MDS/AML with MDS-related gene mutations (n = 87), MDS/AML with MDS-related cytogenetic abnormalities (n = 12), MDS/AML-NOS (n = 19), and AML with CEBPA (n = 3) (Supplementary Table 7). This evidence concerns the gene TP53 and myelodysplastic syndrome.